Clinical trials: Multiple Myeloma
Plasma Cell Myeloma, Residual Disease
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell…
- Trial name
- NCT02389517
- Testing
- Ixazomib Citrate, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Chicago
Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
This is a Phase 2, open-label, multicenter study examining the safety, pharmacokinetics and pharmacodynamics, and best overall response to escalating doses of the proteasome inhibitor NPI-0052 (also known as marizomib) in…
- Trial name
- NCT00461045
- Testing
- MRZ 0.5 mg/m^2
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celgene
Relapsed or Refractory Multiple Myeloma
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT02099539
- Testing
- N-803
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Altor BioScience
Multiple Myeloma
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this Phase 1 study is to characterize the pharmacokinetic (PK) and tolerability of oral ixazomib (MLN9708) when administered in combination with lenalidomide and dexamethasone in adult Asian participants with…
- Trial name
- NCT01645930
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 5 sites in Hong Kong, Singapore and 1 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and…
- Trial name
- NCT02722941
- Testing
- Panobinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Myeloma
A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side…
- Trial name
- NCT01302366
- Testing
- TBL12
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma
- Trial name
- NCT05490771
- Testing
- Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral Neuropathies, Multiple Myeloma
1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma
Patients are asked to be in this study if they have multiple myeloma and are having tingling, numbness and pain from taking bortezomib (velcade®).
- Trial name
- NCT01541644
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Maryland, Baltimore
Multiple Myeloma
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp alfa.
- Trial name
- iinnovate-2 (NCT05556616)
- Testing
- Modakafusp alfa, Lenalidomide, Bortezomib
- Where
- 21 sites in United States, Belgium and 2 more
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439110
- Testing
- Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed and/or Refractory Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
The purpose of this study is to investigate the efficacy and safety of long-term administration of the oral proteasome inhibitor ixazomib as part of ixazomib in combination with lenalidomide and dexamethasone (IRd) therapy in…
- Trial name
- NCT03416374
- Testing
- Ixazomib, Bortezomib, Carfilzomib
- Where
- 23 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Takeda
Multiple Myeloma
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
This is a phase II study, open-label, single institution trial of pomalidomide in GEP-defined, high-risk relapsing/refractory multiple myeloma. Prior therapy must have included lenalidomide.
- Trial name
- NCT01177735
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- University of Arkansas
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hodgkin Disease, Non-Hodgkin Lymphoma
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
- Trial name
- MoxiProph (NCT00398411)
- Testing
- moxifloxacin
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Cologne
Multiple Myeloma
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple…
- Trial name
- NCT01215344
- Testing
- VELCADE, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01718743
- Testing
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Multiple Myeloma
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
The purpose of the study is to determine the safety and efficacy of the use of bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma.
- Trial name
- BVRD (NCT01484626)
- Testing
- Bendamustine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loyola University
Multiple Myeloma and Plasma Cell Neoplasm
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00687674
- Testing
- dexamethasone, sorafenib tosylate, Lenalidomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic